SLV-154 Treatment of Metastatic Solid Tumors

This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with metastatic solid tumors.

Trial Details

NCT ID
NCT06771219
Phase
PHASE1
Sponsor
Solve Therapeutics
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • SLV-154
Locations (sample)
  • Newport Beach, California, United States|33.61891,-117.92895
  • St Louis, Missouri, United States|38.62727,-90.19789
  • East Brunswick, New Jersey, United States|40.42788,-74.41598
  • New York, New York, United States|40.71427,-74.00597
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Men or women (as appropriate for cancer type) of age ≥18 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
  • Histologically or cytologically confirmed diagnosis of solid tumor as documented in medical records with the primary history comprising one of the …
  • Breast cancer

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →